|

Unlocking Mesothelioma’s Secrets: Understanding the Tumor Microenvironment

Unlocking Mesothelioma's Secrets: Understanding the Tumor Microenvironment

Researchers are working hard to understand the area around mesothelioma tumors. This is known as the tumor microenvironment. The tumor microenvironment affects mesothelioma growth and development.

Decoding the Tumor Microenvironment

Malignant mesothelioma is a serious type of cancer that affects the lining of the lungs, heart, and abdomen. It is caused by asbestos exposure. Scientists are always looking for new ways to understand and treat this disease. One important aspect they’re exploring is how the environment around the tumor, known as the tumor microenvironment. This area affects its growth and development.

In a new study, scientists from Wenzhou Medical University in China used advanced computer programs, called machine learning methods. They studied 87 cases of malignant mesothelioma. They collected a lot of information about each case, including data about the tumor’s genes, how it behaves, and the patient’s health.

The scientists wanted to understand how the tumor microenvironment might tell doctors something about how a patient will respond to treatment. The tumor microenvironment includes things like blood vessels, immune cells, and signaling molecules found around and within the tumor.

Beyond the Tumor

The scientists divided the cases into two groups based on something called stromal scores. This helped them understand how the environment around the tumor influenced the patient’s chances of survival.

Next, they looked at the genes inside the tumors to see if there were any important changes. They discovered two genes, called von Willebrand factor (VWF) and FCRL3, that were especially interesting. These genes seemed to play a role in how the tumors grew.

To learn more, the scientists looked at how VWF was linked to the immune system, which helps the body fight off diseases. They found that higher levels of VWF were connected to certain types of immune cells, which could give clues about how the body was reacting to the cancer.

The researchers found that the group with higher stromal scores had a different survival time compared to the group with lower scores. This means that the environment around the tumor really does matter for the patient’s outcome.

They also learned that having a lot of VWF could be a sign that the cancer might be more aggressive. This is important because it helps doctors understand which treatments might work best for each patient.

The scientists for this study are hopeful that their research can help doctors make better treatment decisions for their patients. They say that more clinical trials and observations are needed to learn more about the tumor microenvironment in mesothelioma patients.

Source

Weng J, Chen J. Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma. Medicine (Baltimore). 2023;102(41):e35579. doi:10.1097/MD.0000000000035579. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578691/

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Could Statin Drugs Help Fight Mesothelioma?

    A new study suggests that some of the most popular drugs used to treat high cholesterol may also help combat deadly malignant mesothelioma. That finding comes from Japanese research, published recently in the medical journal, Cancer Letters. The study found a “synergistic effect” in mesothelioma cells between two statin drugs, atorvastatin (Lipitor) and simvastatin (Zocor) and gamma tocotrienol (y-T3), a form of Vitamin E. “Statin+y-T3 combinations induced greater cell growth inhibition more than each single treatment,” write the authors in the summary of their findings. The combination of statin drugs and gamma-tocotrienol appears to work by inhibiting an important metabolic pathway inside the mesothelioma cells, making it impossible for them to synthesize or utilize certain critical molecules. When the researchers…